Multi-omic analysis of chronic myelomonocytic leukemia monocytes reveals metabolic and immune dysregulation leading to altered macrophage polarization.

COI Statement

Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: PBMNC samples were obtained from CMML patients treated at The Christie NHS Foundation Trust (Manchester, UK) recruited to the Manchester Cancer Research Centre Tissue Biobank (initiated with the approval of South Manchester Research Ethics Committee). PBMNCs from age-matched Healthy volunteers were used as controls. All patients and controls gave informed consent according to the Declaration of Helsinki. The study was approved by the UK Health Research Authority (REC: 19/LO/0564).

References:

• Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19.
• Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024;99:1142–65.
• Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood. 2013;121:2186–98.
• Witkowski MT, Dolgalev I, Evensen NA, Ma C, Chambers T, Roberts KG, et al. Extensive remodeling of the immune microenvironment in B cell acute lymphoblastic leukemia. Cancer Cell. 2020;37:867–82.e812.
• Niyongere S, Lucas N, Zhou JM, Sansil S, Pomicter AD, Balasis ME, et al. Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia. 2019;33:205–16.